FY2025 · ended Dec 31, 2025 · Revenue $0 · Filed Mar 11, 2026
Pliant Therapeutics, Inc. (PLRX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $0 and a net loss of $149.3 million. Free cash flow was -$128.7 million. As of Jun 30, 2026 it held $158.1 million in cash and investments and $28.7 million in total debt.
Revenue
$0
Net income
$-149.34M
+29.0% vs prior year
Operating cash flow (TTM)
$-70.89M
+58.1% vs year-ago TTM
Free cash flow (TTM)
$-70.89M
+58.5% vs year-ago TTM
EPS
$-2.43
+30.0% vs prior year
Dividend per share (TTM)
$0.00
Shares outstanding
61.91M
+1.1% vs prior year
Net cash
$129.36M
as of Jun 30, 2026
Operating margin
-11654.7%
FY 2023
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PLRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1746473
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1.6M | $9.7M | $7.6M |
| Operating income | -$156.4M | -$228.4M | -$184.1M | -$127.2M | -$97.5M |
| Net income | -$149.3M | -$210.3M | -$161.3M | -$123.3M | -$97.3M |
| Diluted EPS | -$2.43 | -$3.47 | -$2.75 | -$2.94 | -$2.71 |
| Operating cash flow | -$128.3M | -$155.5M | -$116.4M | -$94.6M | -$75.4M |
| Free cash flow | -$128.7M | -$159.4M | -$117.3M | -$96.4M | -$77.4M |
| Total assets | $225.2M | $396.9M | $512.2M | $350.6M | $221.2M |
| Total liabilities | $44.0M | $92.9M | $38.6M | $37.3M | $22.2M |
| Stockholders' equity | $181.2M | $304.1M | $473.6M | $313.3M | $199.1M |
| Cash and investments | $190.9M | $355.7M | $494.2M | $331.2M | $200.6M |
| Total debt | $29.1M | $60.2M | $11.4M | $15.8M | $7.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 13, 2026 | Jul 9, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 11, 2026 | Jun 11, 2026 |
| 10-Q | Quarterly report | May 11, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 11, 2026 | May 11, 2026 |
All 438 Pliant Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.